Information Journal Paper
APA:
Copy. (2017). Tremelimumab as second-line or thirdline treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. LANCET ONCOLOGY, 18(9), 1261-1273. SID. https://sid.ir/paper/720763/en
Vancouver:
Copy. Tremelimumab as second-line or thirdline treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. LANCET ONCOLOGY[Internet]. 2017;18(9):1261-1273. Available from: https://sid.ir/paper/720763/en
IEEE:
Copy, “Tremelimumab as second-line or thirdline treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial,” LANCET ONCOLOGY, vol. 18, no. 9, pp. 1261–1273, 2017, [Online]. Available: https://sid.ir/paper/720763/en